Amylyx (AMLX) CFO James Frates Receives 22,807-Share Award

What Happened

• James M. Frates, Chief Financial Officer of Amylyx Pharmaceuticals (AMLX), was awarded and acquired 22,807 shares on August 18, 2026. The shares were issued upon vesting of performance share units (PSUs) and are reported as an award/acquisition (code A) with a reported acquisition price of $0.

Key Details

• Transaction date: August 18, 2026 (Period of Report). Form filed August 20, 2026 (timely filing).
• Transaction type/code: Award/Grant (A) — PSUs vested and converted into 22,807 common shares.
• Reported acquisition price/value: $0 (award issuance upon vesting).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Notable footnotes:
  • F1: The shares were PSUs awarded upon achieving performance metrics and vested on Aug 18, 2026.
  • F2–F4, F6: Many shares are held in various family/grantor retained annuity trusts for which Frates serves as trustee; he disclaims beneficial ownership of those trust-held shares except to the extent of any pecuniary interest.
  • F5: Reflects a prior transfer of 40,000 shares to a 2026 GRAT on Aug 7, 2026 (a change in form of ownership exempt under Rule 16a-13).

Context

• These were vested PSUs converting into common shares (a compensation award), not an open-market purchase or sale. Awards and gifts generally reflect compensation decisions or plan-driven vesting rather than direct market sentiment by the insider. No sale or tax-withholding details were reported in the excerpt provided.